Dizman, Nazli
Meza, Luis http://orcid.org/0000-0002-0235-297X
Bergerot, Paulo
Alcantara, Marice
Dorff, Tanya
Lyou, Yung
Frankel, Paul
Cui, Yujie
Mira, Valerie
Llamas, Marian
Hsu, Joann
Zengin, Zeynep
Salgia, Nicholas
Salgia, Sabrina
Malhotra, Jasnoor
Chawla, Neal
Chehrazi-Raffle, Alex
Muddasani, Ramya
Gillece, John
Reining, Lauren
Trent, Jeff
Takahashi, Motomichi http://orcid.org/0000-0003-4773-5904
Oka, Kentaro
Higashi, Seiya
Kortylewski, Marcin http://orcid.org/0000-0002-6003-1816
Highlander, Sarah K. http://orcid.org/0000-0002-3800-4950
Pal, Sumanta K. http://orcid.org/0000-0002-1712-0848
Article History
Received: 26 July 2021
Accepted: 13 January 2022
First Online: 28 February 2022
Competing interests
: N.D. reports a consulting role for Vivreon Bioscience. T.D. reports a consulting/advisory role for Exelixis, Janssen, Bayer and BMS. Y.L. reports a consulting/advisory role for Pfizer, EMD Serano and Seattle Genetics. S.H., K.O. and M.T. report personal fees from Miyarisan Pharmaceuticals. S.K.P. reports a consulting/advisory role for Novartis, Medivation, Astellas Pharma, Pfizer, Aveo, Myriad, Genentech, Exelixis, Bristol-Myers Squibb and Astellas. The other authors declare no competing interests.